Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report

Ikarashi, Daiki; Nakamura, Yasuyuki; Shimodate, Hitoshi; Usui, Yoshitaka; Ujiie, Takashi; Obara, Wataru

doi:10.1016/j.eucr.2019.100839

Cited by 7 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 11 We previously reported the remarkable efficacy of anti‐PD‐1 antibody based on the presence of marked tumor cell infiltration of lymphocytes after treatment. 12 , 13 On the contrary, we also reported rapid progression of advanced RCC after treatment with nivolumab following sunitinib; in this case, there were no expressions of PD‐L1 and CD8 on the tumor sample pretreatment. 14 For the present cases, we found no expression of PD‐L1 on tumor cells, besides CD4 and CD8 lymphocytes infiltration were observed on biopsy specimens; this result was more pronounced in case 2, which consequently responded almost exclusively to pembrolizumab alone.…”

Section: Discussionmentioning

confidence: 66%

“…Interestingly, the infiltration percentage of CD3 and CD8 T cells was reported to be higher in metastatic tumors than in nonmetastatic CDCs 11 . We previously reported the remarkable efficacy of anti‐PD‐1 antibody based on the presence of marked tumor cell infiltration of lymphocytes after treatment 12,13 . On the contrary, we also reported rapid progression of advanced RCC after treatment with nivolumab following sunitinib; in this case, there were no expressions of PD‐L1 and CD8 on the tumor sample pretreatment 14 .…”

Section: Discussionmentioning

confidence: 72%

See 1 more Smart Citation

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction: Immunotherapy-based combinations have become the standard first-line therapy for metastatic renal cell carcinoma. However, combined immunotherapy for renal collecting duct carcinoma had been reported, but its therapeutic efficacy had been unclear.Case presentation: The first case was a 62-year-old man treated with pembrolizumab and axitinib for renal collecting duct carcinoma with multiple bone metastases. After 7 months, the primary and metastatic lesions shrunk and were evaluated as a partial response. The second case was a 71-year-old man treated with pembrolizumab and axitinib for renal collecting duct carcinoma with lymph node and lung metastases. After 9 months, the primary and metastatic lesions shrunk and were evaluated as a partial response. In both cases, the tumor cell expression of programmed death ligand-1 was negative, and CD4 + and CD8 + cells were observed in the tumor. Conclusion: Combined immunotherapy with pembrolizumab and axitinib may be effective for metastatic renal collecting duct carcinoma.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 72%

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Presently, partial or radical nephrectomy is the main curative treatment available since these tumors are notably resistant to both radio-and chemotherapy [6]. However, cases of complete curative treatment have been reported with interleukin-2 (IL-2) and nivolumab-based therapy [7,8]. The clinical benefit of adjuvant interferon-alpha (IFN-α) and IL-2, heat shock protein-peptide complex-96 (HSPPC-96, Vitespen ® ), girentuximab, or vascular endothelial growth factor receptor/tyrosine kinase inhibitor (VEGFR/TKI) for high-risk RCT patients remains unclear, as results of published randomized trials are conflicting [9][10][11][12][13][14].…”

Section: Renal Cell Tumorsmentioning

confidence: 99%

Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs

Outeiro-Pinho

Barros‐Silva

Correia

et al. 2020

Cancers

View full text Add to dashboard Cite

Renal cell tumors (RCT) remain as one of the most common and lethal urological tumors worldwide. Discrimination between (1) benign and malignant disease, (2) indolent and aggressive tumors, and (3) patient responsiveness to a specific therapy is of major clinical importance, allowing for a more efficient patient management. Nonetheless, currently available tools provide limited information and novel strategies are needed. Over the years, a putative role of non-coding RNAs (ncRNAs) as disease biomarkers has gained relevance and is now one of the most prolific fields in biological sciences. Herein, we extensively sought the most significant reports on ncRNAs as potential RCTs’ diagnostic, prognostic, predictive, and monitoring biomarkers. We could conclude that ncRNAs, either alone or in combination with currently used clinical and pathological parameters, might represent key elements to improve patient management, potentiating the implementation of precision medicine. Nevertheless, most ncRNA biomarkers require large-scale validation studies, prior to clinical implementation.

show abstract

“…[ 1 ] However, in many cases, cancer-related symptoms such as pain or malaise increase with the progression of the disease, which hinders the continuation of cancer treatment. Although there are some case reports of dramatic improvement from severe conditions, [ 2 , 3 ] many studies have revealed that end-of-life cancer treatment neither contributes to an improved prognosis nor leads to appropriate palliative care. [ 4 – 9 ]…”

Section: Introductionmentioning

confidence: 99%

Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patients

et al. 2021

View full text Add to dashboard Cite

Decision-making to stop cancer treatment in patients with advanced cancer is stressful, and it significantly influences subsequent end-of-life palliative treatment. However, little is known about the extent to which the patient's self-decisions influenced the prognostic period. This study focused on the patient's self-decision and investigated the impact of the self-decision to stop cancer treatment on their post-cancer treatment survival period and place of death. We retrospectively analyzed 167 cases of advanced genitourinary cancer patients (kidney cancer: 42; bladder cancer: 68; prostate cancer: 57) treated at the University of Fukui Hospital (UFH), who later died because of cancer. Of these, 100 patients decided to stop cancer treatment by themselves (self-decision group), while the families of the remaining 67 patients (family's decision group) decided to stop treatment on their behalf because the patient's decision-making ability was already impaired. Differences in the post-cancer-treatment survival period and place of death between the 2 groups were examined. The association between place of death and survival period was also analyzed. The median survival period after terminating cancer treatment was approximately 6 times longer in the self-decision group (145.5 days in self-decision group vs 23.0 days in family's decision group, P < .001). Proportions for places of death were as follows: among the self-decision group, 42.0% of patients died at UFH, 45.0% at other medical institutions, and 13.0% at home; among the family's decision group, 62.7% died at UFH, 32.8% at other medical institutions, and 4.5% at home. The proportion of patients who died at UFH was significantly higher among the family's decision group ( P = .011). The median survival period was significantly shorter for patients who died at UFH (UFH: 30.0 days; other institutions/home: 161.0 days; P < .001). Significantly longer post-cancer-treatment survival period and higher home death rate were observed among patients whose cancer treatment was terminated based on their self-decision. Our results provide clinical evidence, especially in terms of prognostic period and place of death that support the importance of discussing bad news, such as stopping cancer treatment with patients.

show abstract

Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report

Cited by 7 publications

References 5 publications

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases

Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs

Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patients

Contact Info

Product

Resources

About